EVL Stock Chart & Stats
€3.88
-€0.10(-0.96%)
At close: 4:00 PM EST
€3.88
-€0.10(-0.96%)
Day’s Range― - ―
52-Week Range€3.42 - €8.15
Previous CloseN/A
Volume0.00
Average Volume (3M)179.00
Market Cap
€324.04M
Enterprise Value€383.03
Total Cash (Recent Filing)€49.79M
Total Debt (Recent Filing)€164.90M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Aug 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding65,854,750
10 Day Avg. Volume20
30 Day Avg. Volume179
Financial Highlights & Ratios
PEG Ratio6.73
Price to Book (P/B)-18.55
Price to Sales (P/S)1.44
P/FCF Ratio-8.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.67Price Target Upside226.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.08
Revenue Forecast (FY)€290.13M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue GrowthTTM revenue growth plus ~65% gross margins reflect durable product economics and pricing power for Jeuveau. These structural margins provide room for operating leverage as the commercial footprint scales, supporting long-term margin sustainability and improved cash conversion if growth continues.
Portfolio Expansion (Profhilo U.S. Deal)The Profhilo distribution agreement meaningfully broadens Evolus’s addressable market into skin-quality injectables without upfront cash outlays. Its capital-efficient structure leverages existing commercial channels, diversifies revenue mix, and strengthens practitioner relationships for more resilient long-term growth.
Improving Profitability Momentum & RunwayConsecutive positive adjusted EBITDA quarters and reiterated 2026 guidance signal operational discipline and improving unit economics. Coupled with $49.8M cash and access to $120M in capital, this provides runway to execute launches and capture margin expansion if management sustains execution.
Bears Say
Levered Balance Sheet / Negative EquityNegative shareholders’ equity and elevated debt materially weaken financial flexibility and increase refinancing risk. This structural leverage constrains strategic optionality, magnifies downside in revenue shocks, and can limit the company’s ability to invest or pursue M&A without dilutive or costly financing.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow forces reliance on external capital to fund operations and launches. Continued cash burn increases dilution or debt risk, limits reinvestment capacity, and reduces resilience to slower commercial uptake or tighter capital markets over the medium term.
Competitive Pressure & Small Filler ContributionEvolisse’s current revenue contribution is small and the filler market is flat, while incumbents and new neurotoxin entrants increase competitive intensity. Structural market competition raises required marketing spend and could slow share gains until new mid-face products meaningfully scale.
Evolus News
EVL FAQ
What was Evolus, Inc.’s price range in the past 12 months?
Evolus, Inc. lowest stock price was €3.42 and its highest was €8.15 in the past 12 months.
What is Evolus, Inc.’s market cap?
Evolus, Inc.’s market cap is €324.04M.
When is Evolus, Inc.’s upcoming earnings report date?
Evolus, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 19 days.
How were Evolus, Inc.’s earnings last quarter?
Evolus, Inc. released its earnings results on May 04, 2026. The company reported -€0.04 earnings per share for the quarter, beating the consensus estimate of -€0.099 by €0.059.
Is Evolus, Inc. overvalued?
According to Wall Street analysts Evolus, Inc.’s price is currently Undervalued.
Does Evolus, Inc. pay dividends?
Evolus, Inc. does not currently pay dividends.
What is Evolus, Inc.’s EPS estimate?
Evolus, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Evolus, Inc. have?
Evolus, Inc. has 65,854,750 shares outstanding.
What happened to Evolus, Inc.’s price movement after its last earnings report?
Evolus, Inc. reported an EPS of -€0.04 in its last earnings report, beating expectations of -€0.099. Following the earnings report the stock price went up 5.12%.
Which hedge fund is a major shareholder of Evolus, Inc.?
Currently, no hedge funds are holding shares in DE:EVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€12.67 (226.61% Upside)
€12.67 (226.61% Upside)
Blogger Sentiment
Bullish
DE:EVL Sentiment 70%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.80%
12-Months-Change
Fundamentals
Return on Equity
174.92%
Trailing 12-Months
Asset Growth
3.41%
Trailing 12-Months
Company Description
Evolus, Inc.
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
EVL Stock 12 Month Forecast
Average Price Target
€12.67
▲(226.61% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―